NCT03738878

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Vanderbilt University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the hypothesis that combined angiotensin receptor blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin, substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial tissue-type plasminogen activator (t-PA) release compared to ARB alone. A secondary goal is to determine if there is an interactive effect of ARB/NEP inhibition and dipeptidyl peptidase 4 (DPP4) inhibition on responses to these peptides.

Detailed description

After informed consent is obtained, subjects will undergo a screening history and physical exam, and anti-hypertensive medications will be withdrawn. During this period, blood pressure (BP) will be measured every one to three days. After subjects have been off anti-hypertensive medications for three weeks (four for spironolactone), they will be randomized to four-week treatment with valsartan 160 mg bid (80 mg bid for one week, then 160 mg bid) or LCZ696 200 bid (100 mg bid for one week, then 200 mg bid) in a double-blind fashion. On the morning of the 28th day of study drug, subjects will report to the Vanderbilt Clinical Research Center (CRC) after an overnight fast. Subjects will be studied in the supine position in a temperature-controlled room. They will be instrumented for intra-arterial infusions. Subjects will be given their last dose of study drug. One hour after drug administration, we will measure forearm blood flow (FBF) and give bradykinin, substance P, or BNP. Each peptide will be infused in three graded doses for five minutes. After administration of all three peptides, subjects will be allowed to rest for an hour. Then they will be given a single oral dose of sitagliptin 200 mg and be allowed to rest for 90 minutes. We will repeat baseline measurements and the peptide infusions with an intervening rest period. The four-week study treatment and protocol will be repeated after a three-week washout, until participants complete both arms.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Valsartan	oral valsartan
DRUG	LCZ696	oral LCZ696
DRUG	Bradykinin	Intra-arterial bradykinin at three graded doses
DRUG	Substance P	Intra-arterial substance P at three graded doses
DRUG	BNP	Intra-arterial BNP at three graded doses
DRUG	Sitagliptin	oral sitagliptin

Timeline

• Start date: 2018-11-15
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2018-11-13
• Last updated: 2025-08-03
• Results posted: 2025-08-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study